gutflix
GI learning, personalised

Summary

CORTICOSTEROID-FREE REMISSION IN ANTI-TNF FAILED CROHN'S DISEASE PATIENTS TREATED WITH VEDOLIZUMAB AS SECOND-LINE BIOLOGIC THERAPY: A REAL WORLD DATA REVIEW

Dirk Lindner

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

A systematic review of real-world cohort data found that 37.1% of Crohn's disease patients who failed anti-TNF therapy achieved corticosteroid-free remission at 6 months when treated with vedolizumab as second-line biologic therapy.

KEY POINTS

- Ten real-world studies (N=45 to N=161 per study) of Crohn's disease patients previously exposed to anti-TNF therapy were analyzed for corticosteroid-free remission outcomes with vedolizumab.
- Corticosteroid-free remission at 6 months was achieved in 37.1% (95% CI 33.6-40.5%) of patients, with rates across individual studies ranging from 15.3% to 58.2%.
- Baseline corticosteroid use varied from 15.5% to 51.0% across cohorts but was not related to corticosteroid-free remission rates at 6 months.
- Clinical remission and corticosteroid-free remission rates were almost identical at 1 year in most cohorts, and benefit was established within 6 months after induction.
- The study was sponsored by Takeda, manufacturer of vedolizumab.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/c946bc42-743c-11ee-9943-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.